Potential biomarkers of ductal carcinoma in situ progression

BMC Cancer

Table 1 Patients characteristics

Case ID	Age range (years)	Invasive type	Molecular subtype	Histological type	Histological grade	Invasive nuclear grade	DCIS Nuclear grade	DCIS type	ER^f in DCIS	PR^g in DCIS	Size (mm)	T^h stage	Nⁱ stage	Pathological clinical stage	Myriad test
G1P1	50–60	IDC^a	Luminal B Her negativo	IDC	3	3	N	N	N	N	31	T2	N0	IIa	N > 50
G1P2	50–60	IDC	TN^d	IDC	3	3	N	N	N	N	10	T1b	N0	I	N > 50
G1P3	60–70	IDC	HER2	IDC	3	3	N	N	N	N	33	T2	N1	IIb	N > 50
G1P4	60–70	IDC	Luminal A	IDC	2	2	N	N	N	N	20	T1c	N0	I	N > 50
G1P5	40–50	IDC	Luminal B Her positivo	IDC	1	1	N	N	N	N	40	T2	N0	IIa	N < 50
G1P6	40–50	IDC	Luminal B Her negativo	IDC	2	2	N	N	N	N	20	T1c	N0	I	N < 50
G2P1	70–80	N^b	N	DCIS^e	N	N	3	S, C, M, Co	++++	+++	105	Tis	N0	0	N > 50
G2P2	40–50	N	N	DCIS	N	N	3	S, C, M	–	–	50	Tis	N0	0	N < 50
G2P3	40–50	N	N	DCIS	N	N	3	S, Co, C, M	+++	+++	18	Tis	N0	0	N < 50
G2P4	50–60	N	N	DCIS	N	N	3	S, Co	++++	++	30	Tis	N0	0	N > 50
G2P5	50–60	N	N	DCIS	N	N	3	C, M, Co	+	+	60	Tis	N0	0	N > 50
G2P6	50–60	N	N	DCIS	N	N	3	S, M, Co	+	–	20	Tis	N0	0	N > 50
G3P1	50–60	^*IDC^c	TN	DCIS-IDC	3	3	3	S, C, Co	–	–	30	T1c	N0	I	N > 50
G3P2	60–70	^*IDC	Her2	DCIS-IDC	3	3	3	S, A, M, Co	–	–	100	T2	N1	IIb	N > 50
G3P3	50–60	^*IDC	Luminal B Her negativo	DCIS-IDC	3	3	3	S, C, Co	++++	++	65	T1c	N0	I	N > 50
G3P4	60–70	^*IDC	Her2	DCIS-IDC	2	2	3	S, C	–	–	36	T1a	N1	IIa	N > 50
G3P5	30–40	^*IDC	Luminal B Her negativo	DCIS-IDC	2	2	2	S, C	++++	+	29	T1a	N1	IIa	N > 50
G3P6	50–60	^*IDC	Luminal B Her positivo	DCIS-IDC	3	3	N	S, C, Co	++++	+	N	T1a	N0	I	N > 50

DCIS type: S – solid; M – micropapillary; C – cribriform; A – adherent; Co – comedocarcinoma
Clinical stage as defined by TNM staging [10] metastases have always been absent, so the clinical stage is only extrapolated from T and N
Myriad’s hereditary cancer tests were made according Frank et al. [11] - N < 50 (family history of hereditary cancer absent and breast cancer diagnosed before 50 years of age) and > 50 (family history of hereditary cancer absent and breast cancer diagnosed after 50 years of age)
Histological grade was obtained according Lakhani et al. [12]. For ER and PR: stained slides were examined as follows: “negative” (−) - absence of brown precipitate in cells; the positive samples were labeled as (+) [if there were a few (< 10%) scattered cells with precipitate]; (++) [for large areas (10–50%) of positivity] and (+++) [designated 50 to 100% positivity]
IDC invasive ductal carcinoma
N not available or absent
DCIS-IDC IDC with in-situ component
TN triple negative
DCIS ductal carcinoma in situ
ER estrogen receptor
PR- progesterone receptor
T tumor
N regional lymph node

ISSN: 1471-2407